The 2013 Import and Export Market for Vaccines, Antisera, and Other Blood Fractions in Norway

On the demand side, exporters and strategic planners focusing on vaccines, antisera, and other blood fractions in Norway face a number of questions. Which countries are supplying vaccines, antisera, and other blood fractions to Norway? How important is Norway compared to others in terms of the entire global and regional market? How much do the imports of vaccines, antisera, and other blood fractions vary from one country of origin to another in Norway? On the supply side, Norway also exports vaccines, antisera, and other blood fractions. Which countries receive the most exports from Norway? How are these exports concentrated across buyers? What is the value of these exports and which countries are the largest buyers? This report was created for strategic planners, international marketing executives and import/export managers who are concerned with the market for vaccines, antisera, and other blood fractions in Norway. With the globalization of this market, managers can no longer be contented with a local view. Nor can managers be contented with out-of-date statistics which appear several years after the fact. I have developed a methodology, based on macroeconomic and trade models, to estimate the market for vaccines, antisera, and other blood fractions for those countries serving Norway via exports, or supplying from Norway via imports. It does so for the current year based on a variety of key historical indicators and econometric models. In what follows, Chapter 2 begins by summarizing where Norway fits into the world market for imported and exported vaccines, antisera, and other blood fractions. The total level of imports and exports on a worldwide basis, and those for Norway in particular, is estimated using a model which aggregates across over 150 key country markets and projects these to the current year. From there, each country represents a percent of the world market. This market is served from a number of